U.S. markets open in 4 hours 11 minutes
  • S&P Futures

    4,231.00
    +21.25 (+0.50%)
     
  • Dow Futures

    33,457.00
    +153.00 (+0.46%)
     
  • Nasdaq Futures

    13,383.25
    +72.00 (+0.54%)
     
  • Russell 2000 Futures

    1,988.70
    +12.40 (+0.63%)
     
  • Crude Oil

    94.13
    -0.21 (-0.22%)
     
  • Gold

    1,802.20
    -5.00 (-0.28%)
     
  • Silver

    20.27
    -0.07 (-0.36%)
     
  • EUR/USD

    1.0300
    -0.0026 (-0.25%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.06
    +0.32 (+1.62%)
     
  • GBP/USD

    1.2151
    -0.0052 (-0.42%)
     
  • USD/JPY

    133.2910
    +0.2920 (+0.22%)
     
  • BTC-USD

    23,958.63
    -544.60 (-2.22%)
     
  • CMC Crypto 200

    569.68
    -5.07 (-0.88%)
     
  • FTSE 100

    7,504.98
    +39.07 (+0.52%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
HOOKIPA Pharma Inc
HOOKIPA Pharma Inc

NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.

The Company will not be conducting a conference call in conjunction with this earnings release.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media

Investors

Instinctif Partners

Matt Beck

hookipa@instinctif.com

Executive Director – Investor Relations

+44 (0)20 7457 2020

matthew.beck@hookipapharma.com